http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1323430-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a084f722795b1d4d4932a6f3a4e63cb8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
filingDate 2001-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19cc2f86de7d0484abf6c2edaff0b3fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f05adf20c8c0d939fe7247f67bd2775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6a54aa55d0985d4d5f28a48ddec852a
publicationDate 2003-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1323430-A3
titleOfInvention Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
abstract The present invention refers to a pharmaceutical composition suitable for thentransdermal or transmucosal administration of one or more active agents, in form of angel or a solution, comprising as a permeation enhancers a combination of:n a) saturated fatty alcohol of formula CH 3 -(CH 2 ) n -CH 2 OH or saturated fatty acid CH 3 -(CH 2 ) n -CH 2 COOHnwherein n is an integer number 8 + 22, preferably 8 + 12, mostnpreferably 10, or unsaturated fatty alcohol or fatty acid of formula:nCH 3 (C n H 2(n-1) )-OH or CH 3 (C n H 2(n-1) )-COOH wherein n is an integer number 8 + 22, b) a ternary vehicle or carrier consisting of a C 1 + C 4 alkanol, a polyalcohol innparticular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.
priorityDate 2000-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4952560-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0249397-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524027
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416290180
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8117

Total number of triples: 40.